For the first time, the FDA released over 200 rejection letters sent to drugmakers concerning novel and generic drug applications. This unprecedented transparency initiative, covering decisions from 2020 to 2024, includes only letters for products eventually approved and redacts proprietary information to protect business details. While the move sheds light on aspects of the agency’s review process previously opaque, it excludes complete response letters related to drugs never approved, which remain confidential. The release emphasizes the FDA’s commitment to openness but leaves significant interest in unreleased data unresolved.